Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 96.00 | |
2 mg | In stock | $ 139.00 | |
5 mg | In stock | $ 231.00 | |
10 mg | In stock | $ 393.00 | |
25 mg | In stock | $ 658.00 | |
50 mg | In stock | $ 937.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 242.00 |
Description | Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor. |
Targets&IC50 | ERK2:0.6 nM |
In vitro | AZD-0364 is measured in the ERK2 mass spectrometry and A375 phospho-p90RSK assays (IC50s: 0.6 nM and 5.7 nM). AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as monotherapy. |
In vivo | In the A549 xenograft model, Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle-only control. The combination of Selumetinib and AZD-0364 ethanesulfonic acid results in a reduction in tumor growth. |
Synonyms | AZD-0364 |
Molecular Weight | 494.5 |
Formula | C24H24F2N8O2 |
CAS No. | 2097416-76-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (202.22 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tizaterkib 2097416-76-5 MAPK ERK inhibit AZD0364 Inhibitor Extracellular signal regulated kinases AZD-0364 AZD 0364 inhibitor